Compare SMX Security Matters plc (SMX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SMX Security Matters plc vs Vertex Pharmaceuticals Incorporated — how do they compare? SMX Security Matters plc trades at $16.48 (market cap $17.04M), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7878.5× SMX Security Matters plc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| SMX | VRTX | |
|---|---|---|
Market Cap | $17.04M | $134.25B |
Sector | Technology | Health |
52-Week High | $103.71K | $529.65 |
52-Week Low | $12.87 | $376.62 |
Enterprise Value | -$14.29M | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMX (Security Matters) trades at $16.16, up 2.28% on the day, but technical indicators signal a bearish trend with the stock near its pivot point. The company reported a net loss of $169.18M for 2025, with negative profitability metrics (ROE -819.22%), though recent news highlights a strengthened balance sheet and progress in commercializing its materials traceability platform amid growing regulatory demand for recycled plastics.
The outlook remains high-risk given persistent losses and cash burn, offset by potential from regulatory tailwinds in recycling. Investors face significant execution risk, but the company's niche in material verification could capture value if commercialization accelerates. The stock's viability hinges on reversing operational losses and achieving sustainable revenue growth.
Vertex Pharmaceuticals (VRTX) trades at $525.72, up 0.35% on the day, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales guidance, driven by cystic fibrosis drug strength and new product contributions. Profitability remains robust with a 35% net income margin, though the P/E ratio of 30.85 reflects premium valuation.
Outlook is positive with 84% analyst buy ratings and a $534.25 consensus target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of new launches and sustained CF franchise growth, while any clinical or regulatory setbacks could pressure the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
